Abstract: ObjectiveTo explore the clinical efficacy of neoadjuvant chemotherapy on advanced epithelial ovarian cancer. MethodsFrom May 2006 to March 2010, 60 patients with ⅢⅣ stage advanced epithelial ovarian cancer were collected in Affiliated Cancer Hospital of Shanxi Medical University, which were divided into two groups based on different treatment methods. The observation group used the neoadjuvant chemotherapy, but the control group did not use it. The efficacy, operation time, blood loss, size of residual disease and the level of CA125 were observed to evaluate the safety and clinical efficacy of neoadjuvant chemotherapy. ResultsThe total effective rate in the observation group was 60.0%. The satisfied cytoreductive rate was 70.0%, which was significantly higher than the control group (χ2=5.455, P<0.05). The mean operative time (127.21±27.62) min (t=10.113, P＜0.05), intraoperative mean blood loss (408.5±112.62) ml (t=5.047, P＜0.05) and the level of CA125 (165.26±43.27) U/ml (t=14.100, P<0.05) in the observation group were significantly lower than the control group［189.33±45.81) min，(590.6±162.41) ml，(339.13±51.86) U/ml］. Five year survival rates of the observation group and control group were 36.7% and 26.7% respectively, with significant difference (χ2=8.492, P=0.036). ConclusionNeoadjuvant chemotherapy can play a positive role in the treatment of the patients with advanced epithelial ovarian cancer.

Key words: Ovarian neoplasms, Chemotherapy, adjuvant